NCT03966040View on ClinicalTrials.gov

A Clinical Trial to Evaluate a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

December 16, 2019

Study Completion Date

May 16, 2020

Conditions
Staphylococcus Aureus Infection
Interventions
BIOLOGICAL

Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7

36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0-3-7

BIOLOGICAL

Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7

36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-3-7

BIOLOGICAL

Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7

36 participants will be given three dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7

BIOLOGICAL

Inoculate Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14

36 participants will be given four dose of Staphylococcus aureus vaccine(Escherichia Coli) at day 0/0-7-14

Trial Locations (1)

221000

Suining County Center for Disease Control and Prevention, Xuzhou

Sponsors
All Listed Sponsors
collaborator

Chengdu Olymvax Biopharmaceuticals Inc.

INDUSTRY

collaborator

PLA Army Medical University

UNKNOWN

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK